Greenwich LifeSciences Inc. GLSI
$24.22
▲ +4.47% 24H
About
Greenwich LifeSciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies targeting breast cancer and other HER2/neu-expressing cancers. Its lead product candidate, GP2, is a nine-amino acid peptide derived from the HER2/neu protein, combined with GM-CSF to form GLSI-1…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees4
TickerGLSI
Statistics
Market Cap$355.2M
Revenue (TTM)$0
Net Income-$19.4M
Net Margin—
EPS$-1.43
P/E-16.01
P/S—
P/B64.15
EV/EBITDA-14.02
ROE-676.7%
Dividend Yield—
Price$24.22
Data: Twelve Data · Revenue = mcap / P/S